In:
Advanced Science, Wiley, Vol. 8, No. 12 ( 2021-06)
Abstract:
Success in anticancer immune therapy relies on stimulation of tumor antigen‐specific T lymphocytes and effective infiltration of the T cells into tumor tissue. Here, a therapeutic vaccine that promotes proliferation and tumor infiltration of antigen‐specific T cells in both inflamed and noninflamed tumor types is described. The vaccine consists of STING agonist 2′3′‐cGAMP, TLR9 ligand CpG, and tumor antigen peptides that are loaded into nanoporous microparticles ( μ GCVax). μ GCVax is effective in inhibiting lung metastatic melanoma, primary breast cancer, and subcutaneous colorectal cancer in their respective murine models, including functional cure of HER2‐positive breast cancer. Mechanistically, μ GCVax potently stimulates type I interferon expression in dendritic cells, and promotes CD8 + and CD103 + dendritic cell maturation and migration to lymph nodes and other lymphatic tissues. Antitumor responses are dependent on TLR9 and interferon α / β receptor signaling, and to a less extent on STING signaling. These results demonstrate a high potential for μ GCVax in mediating antitumor immunity in personalized cancer therapy.
Type of Medium:
Online Resource
ISSN:
2198-3844
,
2198-3844
DOI:
10.1002/advs.202100166
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2808093-2
Bookmarklink